Michael P. Veve PharmD, MPH
Assistant Professor (Clinical)
Michael P. Veve PharmD, MPH
Degrees and Certifications
- 2020 - Master of Public Health, Wayne State University School of Medicine, Detroit, MI
- 2017 - Fellowship in Infectious Diseases Outcomes Research, Henry Ford Hospital/Wayne State University, Detroit, MI
- 2015 - Pharmacy Practice Residency, Henry Ford Hospital, Detroit, MI
- 2014 - Doctor of Pharmacy, Albany College of Pharmacy and Health Sciences, Albany, NY
Positions and Employment
- 2020-Present - Clinical Assistant Professor, Wayne State University, College of Pharmacy, Detroit, MI
- 2020-Present - Clinical Pharmacy Specialist, Infectious Diseases, Henry Ford Health System, Detroit, MI
- 2017–2020- Clinical Assistant Professor, University of Tennessee Health Science Center, College of Pharmacy, Knoxville, TN
Awards and Honors
- 2019 - Professor of the Year, 2018-2019, University of Tennessee Health Science Center College of Pharmacy
- 2016 - IDWeek Travel Grant recipient
- 2015 - ASM ICAAC Infectious Diseases Fellows Grant recipient
- 2015-2017 - Making a Difference in Infectious Diseases, Travel Grant recipient
- 2020–Present - American Public Health Association
- 2018–2020- Tennessee Department of Health, Multi-Disciplinary Advisory Group on Healthcare
- 2018–Present - Infectious Diseases Educator Network
- 2018–2020 - Tennessee Pharmacists Association
- 2017–Present - American Association of Colleges of Pharmacy
- 2017–2019 - The Society for Healthcare Epidemiology of America
- 2016–2017 - Infectious Diseases Society of America
- 2015–Present - Making a Difference in Infectious Diseases (MAD-ID) Research Network
- 2015–Present - Society of Infectious Diseases Pharmacists, Associate member
Areas of Expertise
- Antimicrobial stewardship
- Public Health practice
Primary Research Interest
- Implementation and assessment of novel antimicrobial stewardship interventions
- Epidemilogy and outcomes of multi-drug resistant pathogens
- Antimicrobial optimization in specialized patient populations
- Prevention and treatment optimization of infections due to injection-drug use
Select Peer-Reviewed Publications
1. Kelly MC, Yeager SD, Shorman MA, Wright LR, Veve MP. Incidence and predictors of Gram-negative infections in hospitalized people who inject drugs with injection drug use-attributable infections. Antimicrob Agents Chemother. 2021. In press.
2. Cernasev A, Veve MP, Summers NA, Hohmeier KC, Kumar S. Importance of Pharmacist-Patient Relationships in People Living with HIV and Opioid Use Disorder. Accepted at Exploratory Research in Clinical and Social Pharmacy. 2021. In press.
3. Alosaimy S, Lagnf AM, Morrisette T, Scipione MR, Zhao JJ, Jorgensen SCJ, Mynatt R, Carlson TJ, Jo J, Garey KW, Allen D, DeRonde K, Vega A, Abbo LM, Venugopalan V, Athans V, Saw S, Claeys KC, Miller M, Veve MP, Kufel WD, Amaya L, Yost C, Ortwine J, Davis SL, Rybak MJ. Real-world multi-center experience with meropenem-vaborbactam for multidrug-resistant Gram-negative bacterial infections. Accepted at Open Forum Infect Dis. 2021. In press.
4. Cernasev A, Frederick KD, Hall EA, Veve MP, Hohmeier KC. “Don’t label them as addicts!” Student pharmacists’ views on the stigma associated with opioid use disorder. Accepted for publication at Innov Pharm. 2021. In press.
5. Veve MP, Akhtar Y, McKeown PP, Morelli MK, Shorman MA. Percutaneous mechanical aspiration vs valve surgery for tricuspid valve endocarditis in people who inject drugs. Ann Thorac Surg. 2021 May;111(5):1451-1457.
6. Yeager SD, Oliver JE, Shorman MA, Wright LR, Veve MP. Comparison of linezolid step-down therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections. Int J Antimicrob Agents. 2021 Mar 27:106329.
7. Cernasev A, Kodidela S, Veve MP, Cory TJ, Jasmin H, Kumar S. A narrative systematic literature review: a focus on qualitative studies on HIV and medication assisted therapy in the United States. Pharmacy (Basel). 2021 Mar 23;9(1):67.
8. Morelli MK, Veve MP, Lorson W, Shorman MA. Candida spp. infective endocarditis: characteristics and outcomes of twenty cases with a focus on injection drug use as a predisposing risk factor. Mycoses. 2021 Feb;64(2):181-186.
9. Morrisette T, Alosaimy S, Philley JV, Sigler C, Howard C, Webb AJ, Veve MP, Barger ML, Bouchard J, Gore TW, Lagnf AM, Ansari I, Mejia-Chew C, Cohen KA, Rybak MJ. Preliminary, real-world, multi-center experience with omadacycline for Mycobacterium abscessus infections. Open Forum Infect Dis. 2021 Jan 7;8(2):ofab002.
10. Cernasev A, Veve MP, Talbott T, Hall EA, Hohmeier KC. Student pharmacists’ perceptions and stigma surrounding naloxone use in patients with opioid use disorder: a mixed methods evaluation. Pharmacy (Basel). 2020 Nov;8, 205.
11. Veve MP, Patel N, Smith ZA, Yeager SD, Wright LR, Shorman MA. Comparison of dalbavancin to standard of care for outpatient treatment of invasive Gram-positive infections. Inter J Antimicrob Agents. 2020 Dec;56(6):106210.
12. Cooksey GE, Moye RA, Epps JL, Patel N, Shorman MA, Veve MP. Impact of a plan of care protocol on patient outcomes in people who inject drugs with infective endocarditis. J Infect Dis. 2020 Sep 2;222(Supplement_5):S506-S512.
13. Cernasev A, Veve MP, Cory TJ, Summers NA, Miller M, Kodidela S, Kumar S. Opioid use disorders in people living with HIV/AIDS: a review of implications for patient outcomes, drug interactions, and neurocognitive disorders. Pharmacy (Basel). 2020 Sep 11;8(3):E168.
14. Hall E, Cernasev A, Nastritdinova U, Veve MP, Hohmeier K. Student pharmacist perceptions of opioid use and stigma. Pharmacy (Basel). 2020 Aug 14;8(3):E144.
15. Mercuro NJ, Veve MP. Clinical utility of lefamulin: if not now, when? Curr Infect Dis Rep. 2020;22(9):25.
16. Morelli MK, Veve MP, Shorman MA. Maternal bacteremia caused by Staphylococcus aureus with a focus on infective endocarditis. Open Forum Infect Dis. 2020 Jun 19;7(8):ofaa239.
17. Veve MP, McCurry ED, Cooksey GE, Shorman MA. Epidemiology and outcomes of Non-HACEK infective endocarditis in the southeast United States. PLOS One. 2020 Mar 10;15(3):e0230199.
18. Alosaimy S, Jorgensen SCJ, Lagnf Am, Melvin S, Mynatt RP, Carlson TJ, Garey KW, Allen D, Venugopalan V, Veve M, Athans V, Saw S, Yost CN, Davis SL, Rybak MJ. Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious Gram-negative bacterial infections. Open Forum Infect Dis. 2020 Feb 19;7(3):ofaa051.
19. Jorgensen SCJ, Murray KP, Lagnf AM, Melvin S, Bhatia S, Shamim MD, Smith JR, Brade KD, Simon S, Nagel J, Williams K, Ortwine J, Veve MP, Truong J, Davis SL, Rybak MJ. A multicenter evaluation of vancomycin-associated acute kidney injury in hospitalized patients with acute bacterial skin and skin structure infections. Infect Dis Ther. 2020 Mar;9(1):89-106.
20. Lorson W, Veve MP, Heidel E, Shorman MA. The role of troponin as a predictor of inpatient mortality in infective endocarditis. BMC Infect Dis. 2020 Jan 8;20(1):24.
21. Pogue JM, Kaye KS, Veve MP, Gerlach A, Patel TS, Davis SL, Dhar S, Puzniak L, File TM, Bonomo RA, Perez F. Real world treatment of multi-drug resistant (MDR) or extensively-drug resistant (XDR) P. aeruginosa infections with ceftolozane/tazobactam (C/T) versus a polymyxin or aminoglycoside (Poly/AG) based regimen: a multicenter comparative effectiveness study. Clin Infect Dis. 2020;71(2):304-310.
22. Veve MP, January SE, Kenney RM, Zoratti EM, Zervos MJ, Davis SL. Impact of reported β-lactam allergy on management of methicillin-sensitive Staphylococcus aureus bloodstream infections. J Pharm Pract. 2020 Dec;33(6):809-814.
23. Humphrey C, Veve MP, Walker B, Shorman MA. Long-term vancomycin use had low risk of ototoxicity. PLOS One. 2019 Nov 6;14(11):e0224561.
24. Chastain DB, Veve MP, Wagner JL. Abnormal QTc syndrome in HIV-infected patients: A review of prevalence and risk factors. Antivir Ther. 2019;24(6):459-465.
25. Chaudhry SB, Veve MP, Wagner JL. Cephalosporins: A focus on side chains and β-Lactam cross-reactivity. Pharmacy. 2019 Jul 29;7(3). pii: E103.
26. Veve MP, Stuart M, Davis SL. Comparison of neutropenia associated with ceftaroline or ceftriaxone in patients receiving at least 7 Days of therapy for severe infections. Pharmacotherapy. 2019 Aug;39(8):809-815.
27. Butts A, Reitler P, Nishimoto AT, DeJarnette C, Estredge LR, Peters TL, Veve MP, Rogers PD, Palmer GE. A systematic screen reveals a wide variety of approved medications induce antifungal resistance in several Candida species. Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00054-19.
28. Veve MP, Wagner JL. Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharmacotherapy. 2018 Sep;38(9):935-946.
29. Veve MP, Greene JB, Williams AM, Davis SL, Lu N, Shnayder Y, Li DX, Noureldine SI, Richmon JD, Lin LO, Hanasono MM, Pipkorn P, Jackson RS, Hornig JD, Light T, Wax MK, Yiu Y, Bekeny J, Old M, Hernandez D, Patel UA, Ghanem TA. Multicenter assessment of antibiotic prophylaxis spectrum on surgical infections in head and neck cancer microvascular reconstruction. Otolaryngol Head Neck Surg. 2018 Jul;159(1):59-67.
30. Athans V, Veve MP, Davis SL. Trowels and tribulations: review of antimicrobial-impregnated bone cements in prosthetic joint surgery. Pharmacotherapy. 2017 Dec;37(12):1565-1577.
31. Veve MP, Davis SL, Williams AM, McKinnon JE, Ghanem TA. Considerations for antibiotic prophylaxis in head and neck cancer surgery. Oral Oncology. 2017 Sep 21. pii: S1368-8375(17)30281-6.
32. Flynt LK, Veve MP, Samuel LP, Tibbetts RJ. Ceftolozane-tazobactam susceptibility testing of Pseudomonas aeruginosa: a comparison of Etest to broth microdilution. J Clin Microbiol. 2016 Dec 28;55(1):334-335.
33. Veve MP, Wagner JL, Kenney RM, Grunwald JM, Davis SL. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended spectrum beta-lactamase urinary tract infections. Int J Antimicrob Agents. 2016 Jul;48(1):56-60.
34. Patel N, Veve M, Nasiri M, Bliss S, McNutt LA, Lazariu V, Miller CD. Predicting the probability of experiencing clinically significant drug-drug interactions involving boceprevir-containing hepatitis C therapy among patients co-infected with hepatitis C and HIV. AIDS Patient Care STDS. 2014 Oct;28(10):513-6.
35. Patel N, Veve M, Bliss S, Nasiri M, McNutt LA, Lazariu V, Roman M, Miller CD. Prevalence and predictors of important telaprevir drug interactions among patients co-infected with hepatitis C and human immunodeficiency virus. J Pharm Technol. 2014 Oct;30(5):159-67.
36. Patel N, Veve M, Kwon S, McNutt LA, Fish D, Miller CD. Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation. HIV Medicine. 2013 Sep; 14(8):463-71.
37. Patel N, Abdelsayed S, Veve M, Miller CD. Predictors of clinically significant drug-drug interactions among patients treated with non-nucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Ann Pharmacother. 2011 Mar;45(3):317-24.